BRBR Investor Alert: BellRing Brands (BRBR) Facing Securities Class Action Over Alleged Artificial Growth and $2.9 Billion Value Wipeout - Hagens Berman [Accessibility Statement] Skip NavigationSAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is issuing an updated notice to investors in BellRing Brands, Inc. (NYSE: BRBR) regarding the March 23, 2026, lead plaintiff deadline accusing BellRing and certain of BellRing's top executives of securities fraud.[CLICK HE ...

Fermi (FRMI) Faces Securities Class Action Over Alleged $150M Anchor Tenant Exit - Hagens Berman [Accessibility Statement] Skip NavigationPartner Reed Kathrein Scrutinizing Claims of High Conviction Against Revealed Construction Funding Collapse and 33% Stock CrashSAN FRANCISCO, Feb. 20, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is issuing an updated notice to investors in Fermi Inc. (NASDAQ: FRMI) regarding the March 6, 2026, lead plaintiff deadline in a pending securities cla ...

Core Viewpoint - Hagens Berman is investigating Varonis Systems, Inc. (NASDAQ: VRNS) over allegations of failing to disclose significant issues related to its transition to a Software-as-a-Service (SaaS) model, which has led to a substantial decline in revenue and stock value [1]. Group 1: Allegations and Lawsuit Details - The lawsuit claims that Varonis executives concealed renewal softness in its Federal vertical and legacy on-premises business while promoting a successful transition to SaaS [1]. - Following a disclosure on October 28, 2025, Varonis reported a 63.9% year-over-year decline in term license revenue and a reduced Annual Recurring Revenue (ARR) outlook, resulting in a 48% drop in stock price, equating to a loss of approximately $3.8 billion in market value [1]. - The investigation focuses on whether Varonis violated federal securities laws by failing to disclose the significant decline in renewals and the challenges in converting existing customers to the SaaS model [1]. Group 2: Financial Impact and Stock Performance - On the news of the revenue decline, Varonis shares plummeted from $63.00 to $32.34 in a single day, representing a nearly 50% loss in shareholder value [1]. - The company significantly reduced its Q4 revenue and full-year ARR guidance following the Q3 performance miss, indicating a serious impact on its financial outlook [1]. - The lawsuit alleges that Varonis misrepresented its ability to convert on-premises customers to SaaS, claiming strong retention and renewal rates, which were contradicted by the actual performance [1]. Group 3: Next Steps for Investors - Hagens Berman is advising investors who purchased VRNS shares during the class period from February 4, 2025, to October 28, 2025, and experienced substantial losses to contact the firm [1]. - The lead plaintiff deadline for the pending lawsuit is set for March 9, 2026, urging affected investors to take action [1].

Hagens Berman Investigating Claims Against Ardent Health (ARDT) Over Alleged $97M Accounting Shock and "180-Day Cliff" Reserves [Accessibility Statement] Skip NavigationARDT Investors with Losses Encouraged to Contact the FirmSAN FRANCISCO, Feb. 20, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is notifying investors in Ardent Health, Inc. (NYSE: ARDT) regarding the March 9, 2026, lead plaintiff deadline in a pending securities class action the company and certain of its top execut ...

Core Viewpoint - Hagens Berman is investigating Zimmer Biomet Holdings, Inc. (ZBH) due to concerns over the company's "high confidence" assurances regarding its 2025 revenue targets following a 15% stock decline and reduced revenue guidance [1] Group 1: Investigation Focus - The investigation examines whether Zimmer Biomet's senior management misled investors about the stability of its international business, particularly in emerging markets [1] - The firm is looking into potential violations of federal securities laws related to overly optimistic guidance while concealing operational disruptions [1] Group 2: Recent Developments - On November 5, 2025, Zimmer Biomet reported a year-over-year organic revenue growth of only 5%, significantly missing its forecast and reducing its top-line organic revenue growth forecast to 4% [1] - The company disclosed distributor order cancellations in emerging markets, particularly in the Middle East and Eastern Europe, and acknowledged serious headwinds in Latin America [1] - Following these revelations, CEO Ivan Tornos stated the need for more measured external commentary, which contributed to the 15% drop in stock price on the same day [1] Group 3: Previous Assurances - In an August 7, 2025 earnings call, management expressed "very high" confidence in achieving a year-over-year organic revenue growth forecast of 3.5% to 4.5%, attributing it to emerging markets distributor purchases [1] - These optimistic statements led to a 7% increase in the company's share price on that day [1]

Core Insights - Hagens Berman is investigating BellRing Brands, Inc. (NYSE: BRBR) for alleged securities fraud related to misleading statements about sales growth drivers [1] - The lawsuit claims that BellRing's reported sales growth was artificially inflated due to retailers hoarding inventory, leading to a significant drop in share price when the truth was revealed [1] Company Allegations - The lawsuit alleges that BellRing and its executives misled investors regarding the sustainability and drivers of its sales growth, as well as the competitive landscape affecting demand for its products [1] - Key admissions from BellRing's CFO indicated that retailers were hoarding inventory to avoid stock shortages, which was downplayed as a non-issue for consumption [1] Financial Impact - Following the release of disappointing Q3 2025 financial results, BellRing's share price fell by $17.46, a decrease of 33% [1] - The lawsuit claims that the strong sales reported during the class period were not reflective of actual consumer demand but rather due to temporary inventory stockpiling by retailers [1] Next Steps for Investors - Investors who suffered losses from BRBR shares purchased between November 19, 2024, and August 4, 2025, are encouraged to contact Hagens Berman before the lead plaintiff deadline of March 23, 2026 [1]

Core Viewpoint - Ardent Health, Inc. is facing a securities class action lawsuit due to allegations of misleading investors regarding its revenue recognition systems and professional liability reserves, leading to significant financial repercussions for the company [1] Allegations of the Class Action - The lawsuit claims that Ardent Health misrepresented its financial health, resulting in a nearly 34% stock price drop following disclosures made on November 12, 2025 [1] - A $54 million increase in professional liability reserves was recorded, attributed to recent settlements and ongoing litigation, as well as broader industry trends such as social inflation [1] - Ardent Health disclosed a revenue reduction of $42.6 million due to a change in accounting methods for estimating the collectability of accounts receivable [1] - The company allegedly did not maintain sufficient professional malpractice liability insurance and had inadequate professional liability reserves [1] - The complaint highlights that Ardent's method of using a "180-day cliff" for reserves contradicted its claims of conducting "detailed reviews" of receivables, suggesting inflated receivables during the class period [1] Next Steps for Investors - Investors who purchased Ardent Health shares between July 18, 2024, and November 12, 2025, are encouraged to contact the law firm Hagens Berman, with a lead plaintiff deadline set for March 9, 2026 [1]

Core Viewpoint - Varonis Systems, Inc. is facing a securities class action lawsuit due to allegations of misleading investors about its transition to a Software-as-a-Service (SaaS) model, which resulted in significant financial losses for shareholders [1]. Company Performance - The lawsuit claims that Varonis executives misrepresented the company's ability to convert its legacy on-premise customer base to its new SaaS platform, leading to a 63.9% year-over-year decline in term license subscription revenues disclosed on October 28, 2025 [1]. - Following this disclosure, Varonis's stock price plummeted by 48%, dropping from $63.00 to $32.34, resulting in a loss of approximately $3.8 billion in market capitalization [1]. Allegations of Misleading Statements - The litigation alleges that Varonis provided false assurances regarding its SaaS transition, claiming it was "well on our way to becoming a SaaS company" and that it would "accelerate [its] SaaS transition" [1]. - The company reportedly misrepresented its conversion potential, stating that it had a "massive opportunity to increase the ARR from our existing customer base," while the reality indicated a struggle to convince on-premises users to migrate [1]. Financial Guidance and Performance Issues - Following a disappointing Q3 performance, Varonis significantly reduced its Q4 revenue and full-year annual recurring revenue (ARR) guidance [1]. - The lawsuit highlights that weaker renewals in both the Federal vertical and non-Federal on-prem subscription business contributed to the company's performance miss, contradicting previous optimistic statements from Varonis [1].

Core Viewpoint - Hagens Berman is notifying investors in Fermi Inc. (NASDAQ: FRMI) about a pending securities class action related to alleged misrepresentations regarding the demand for its Project Matador AI data center and the stability of its primary tenant [1] Summary by Relevant Sections Allegations of Misrepresentation - The lawsuit claims that Fermi misrepresented the demand for its flagship Project Matador and the reliability of its primary anchor tenant [1] - The complaint states that the misstatements were revealed on December 12, 2025, when Fermi announced the termination of a $150 million Advance in Aid of Construction Agreement (AICA) by its first tenant, leading to a nearly 34% drop in stock price [1] Class Action Details - The class action seeks to represent purchasers of Fermi Inc. common stock related to the October 2025 IPO and securities acquired between October 1, 2025, and December 11, 2025 [1] - Following the announcement of the AICA termination, Fermi's stock price fell 33.8% in one day, trading as low as $8.59 per share, a 59% decline from the IPO price of $21.00 per share [1] Concealed Risks and Overstatements - The complaint alleges that Fermi concealed risks associated with relying on a single tenant's funding commitment for Project Matador and overstated the actual demand for its multi-gigawatt capacity to attract investors [1]

Core Viewpoint - Coupang, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding its cybersecurity measures, particularly related to a significant data breach affecting 33.7 million accounts, which went undetected for nearly six months [2][7]. Group 1: Allegations and Impact - The lawsuit claims that Coupang misrepresented its "proactive security" and "administrative safeguards" while failing to detect a data breach that allowed a former employee to access sensitive customer information [2][7]. - The breach has resulted in a compensation plan of approximately $1.2 billion (1.685 trillion won) and the resignation of CEO Park Dae-joon, leading to a loss of over $8 billion in market value [2][7]. - Coupang acknowledged awareness of the cybersecurity incident on November 18, 2025, just 11 days before public disclosure, indicating a significant delay in informing stakeholders [7]. Group 2: Investigation and Legal Proceedings - Hagens Berman, a shareholder rights firm, is investigating the claims and has set a lead plaintiff deadline of February 17, 2026, for investors who suffered losses during the class period from May 7, 2025, to December 16, 2025 [1][5]. - The investigation focuses on Coupang's alleged failure to maintain adequate internal controls that allowed unauthorized access to customer accounts [7]. - The firm is encouraging affected investors to contact them for potential participation in the lawsuit [1][5].